Information Provided By:
Fly News Breaks for May 20, 2019
INCY
May 20, 2019 | 16:19 EDT
Credit Suisse analyst Evan Seigerman started Incyte with a Neutral rating and $75 price target. The analyst wants to see more clinical evidence and trial execution in the company's its pipeline following last year's failure of epacadostat before coming more positive on the stock.